Conversely, in COAD cases with low or stable MSI, MARCHF9 expression exhibited an opposite significance, potentially indicating a protective or neutral role in survival outcomes (Figure 3(d), P=0.031). Here, MARCHF9 is linked to colon adenocarcinoma.